Financial relationships and prescribing practices between physicians and drug companies

In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.

The study evaluated prescribing of orally-administered cancer drugs in 2013 through 2015 for four cancers: prostate cancer (abiraterone, enzalutamide), kidney cancer (axitinib, everolimus, pazopanib, sorafenib, sunitinib), lung cancer (afatinib, erlotinib), and (dasatinib, imatinib, nilotinib).

Among the 2,766 physicians in the study, those who received payments for a drug within three consecutive years had increased prescribing of that drug for , chronic myeloid leukemia, and lung cancer, but not for prostate cancer.

"These findings add to a growing body of work that suggests physicians are more likely to use drugs made by companies that have given them money in the past," said lead author Dr. Aaron Mitchell, of Memorial Sloan Kettering Cancer Center.


Explore further

Payments to doctors linked to prescription practices for two cancer types

More information: The Oncologist (2019). DOI: 10.1002/onco.12827 , https://onlinelibrary.wiley.com/journal/1549490x
Provided by Wiley
Citation: Financial relationships and prescribing practices between physicians and drug companies (2019, February 6) retrieved 23 May 2019 from https://medicalxpress.com/news/2019-02-financial-relationships-physicians-drug-companies.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more